Clinical development directions in oncolytic viral therapy

Cancer Gene Therapy

Volumn 18, Issue 5, 2011, Pages 305-317

  Eager, R M ^a,b   Nemunaitis, J ^a,b,c,d  

^a Mary Crowley Cancer Research Centers   (United States)

^b Mary Crowley Cancer Research Centers   (United States)

^c TEXAS ONCOLOGY   (United States)

^d MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

adenoviruses; herpes simplex virus; oncolytic viruses; virotherapy

Indexed keywords

ONCOLYTIC VIRUS; ONYX 015; PROTEIN; TELOMELYSIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER THERAPY; DNA VIRUS; DRUG SAFETY; EXPERIMENTAL THERAPY; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; RNA VIRUS; TREATMENT RESPONSE; VIROTHERAPY;

ADENOVIRIDAE; GENETIC ENGINEERING; HUMANS; NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; REOVIRIDAE; SIMPLEXVIRUS; VACCINIA VIRUS;

RNA VIRUSES; SIMPLEXVIRUS;

EID: 79954675872     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.7     Document Type: Review

References (208)

1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376. (Pubitemid 26353341)
2. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645. (Pubitemid 27264973)
3. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallik-rein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for pros-tate cancer therapy. Cancer Res 1999; 59: 1498-1504. (Pubitemid 29160117)
4. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203. (Pubitemid 29418725)
5. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
6. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Human Gene Ther 1998; 9: 1323-1333. (Pubitemid 28312897)
7. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12. (Pubitemid 30066345)
8. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
9. Johnson L. Cytosine deaminase-armed selectively-replicat-ing adenovirus for the treatment of cancer. Proc Am Assoc Cancer Res 2002; 43: 3257.
10. Hallenbeck PL, Jacubczak J, Ryan P, Hawkins L, Ling X, Forry-Schaudies S. Oncolytic adenoviruses dependent on two prevalent alterations in human cancer: Disregulation of the Rb-pathway and telomerase. Mol Ther 2002; 5: 165.
11. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000; 74: 6147-6155. (Pubitemid 30412986)
12. Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 2001; 19: 1035-1041. (Pubitemid 33041887)
13. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 2007; 7: 191-201. (Pubitemid 46348634)
14. Fujiwara T, Urata Y, Tanaka N. Diagnostic and ther-apeutic application of telomerase-specific oncolytic adeno-viral agents. Front Biosci 2008; 13: 1881-1886. (Pubitemid 351599740)
15. Hansen RM, Libnoch JA. Remission of chronic lympho-cytic leukemia after smallpox vaccination. Arch Intern Med 1978; 138: 1137-1138. (Pubitemid 10220766)
16. Bousser J, Zittoun R. Prolonged spontaneous remission of chronic lymphoid leukemia. Nouv Rev Fr Hematol 1965; 5: 498-501.
17. Vladimirskaia EB. A case of prolonged spontaneous remission in a patient with chronic lymphatic leukemia. Probl Gematol Pereliv Krovi 1962; 7: 51-54.
18. Weintraub LR. Lymphosarcoma. JAMA 1969; 210: 1590-1591.
19. Sinkovics JG. Oncolytic viruses and viral oncolysates. Ann Immunol Hung 1986; 26: 271-290.
20. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971; 2: 105-106.
21. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin's disease after measles. Lancet 1981; 1: 1112.
22. Bierman HR, Crile DM, Dod KS, Kelly KH, Petrakis NL, White LP et al. Remissions in leukemia of childhood follo-wing acute infectious disease: staphylococcus and strepto-coccus, varicella, and feline panleukopenia. Cancer 1953; 6: 591-605.
23. Pelner L, Fowler GA, Nauts HC. Effects of concurrent infections and their toxins on the course of leukemia. Acta Med Scand 1958; 162(Suppl 338): 1-47.
24. London RE. Multiple myeloma: report of a case showing unusual remission lasting two years following severe hepatitis. Ann Intern Med 1955; 43: 191-201.
25. Dock G. Influence of complicating diseases upon leukemia. Am J Med Sci 1904; 127: 563-592.
26. Bierman HR, Hammon W, Eddie BU, Meyer KF, Shimkin MB. The effect of viruses and bacterial infections on neo-plastic diseases. Cancer Res 1950; 10: 203-204.
27. Hernandez A. Observacion de un case de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares, post-sarampion. Rev Med Cubana 1949; 60: 120-125.
28. De Pace NG. Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica. Ginecologia 1912; 9: 82-88.
29. Pack GT. Note of the experimental use of rabies vaccine for melanomatosis. Arch Dermtol and Syphilol 1950; 62: 694-695.
30. Southam CM. Present status of oncolytic virus studies. Trans NY Acad Sci 1960; 22: 657-673.
31. Asada T. Treatment of human cancer with mumps virus. Cancer 1974; 34: 1907-1928.
32. Yamanishi K, Takahashi M, Kurimura T, Ueda S, Minekawa Y. Studies on live mumps virus vaccine. 3. Evaluation of newly developed live mumps virus vaccine. Biken J 1970; 13: 157-161.
33. Harris RJC (ed). Carcinolytic viruses. Biological Ap-proaches to Cancer Chemotherapy: Academic Press, New York, 1961.
34. Harris JE, Sinkovics JG. The Immunology of Malignant Disease. Mosby: St Louis, 1976, 180-182, 464-467, 475-478pp.
35. Hoster HA, Zanes RP, von Haam E. Studies in Hodgkin's syndrome. Cancer Res 1949; 9: 473-480.
36. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 1992; 11: 3045-3052.
37. Gannon JV, Lane DP. p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature 1987; 329: 456-458. (Pubitemid 17128318)
38. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359-6366.
39. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806. (Pubitemid 30159332)
40. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298. (Pubitemid 32112839)
41. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885. (Pubitemid 30644745)
42. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562-1569. (Pubitemid 34260536)
43. Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003; 10: 341-352. (Pubitemid 36528778)
44. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, Sarraf C et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocel-lular carcinoma. Cancer Gene Ther 2002; 9: 254-259. (Pubitemid 34205499)
45. Reid T, Sze D, Galanis E, Abbruzzese J, Andrews J, Rubin J et al. Intra-arterial administration of a replication-selective adenovirus ONYX-015 in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biological activity. (abstr 793). Proc Am Soc Clin Oncol 2003; 22: 198.
46. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8: 746-759. (Pubitemid 32509788)
47. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-315. (Pubitemid 32237064)
48. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079. (Pubitemid 35244455)
49. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with in-travenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561. (Pubitemid 36182584)
50. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson III A, Galanis E et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-1504. (Pubitemid 46594102)
51. Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, Zwiebel J et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003; 9: 693-702. (Pubitemid 36182602)
52. Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, Sands B et al. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther 2007; 14: 885-893. (Pubitemid 47557221)
53. Nemunaitis J, Edelman J. Selectively replicating viral vectors. Cancer Gene Ther 2002; 9: 987-1000. (Pubitemid 35469142)
54. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001; 8: 1618-1626. (Pubitemid 33085583)
55. Kirn D. The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept. Mol Ther 2006; 13: 237-238. (Pubitemid 43056888)
56. Li JL, Liu HL, Zhang XR, Xu JP, Hu WK, Liang M et al. A phase I trial of intratumoral administration of recombi-nant oncolytic adenovirus overexpressing HSP70 in ad-vanced solid tumor patients. Gene Ther 2009; 16: 376-382.
57. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001; 10: 677-685. (Pubitemid 32331575)
58. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10(1 Pt 1): 285-292. (Pubitemid 38114191)
59. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75-111. (Pubitemid 38121748)
60. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010; 18: 429-434.
61. Robert MS, Lorence RM, Groene WS, Rabin H, Von Borstel RW (inventors). Treatment of neoplasms with viruses. 1999.
62. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825. (Pubitemid 30469434)
63. Lorence RM, Roberts MS, Groene WS, Rabin H. Replica-tion-competent, oncolytic Newcastle disease virus for cancer therapy. Monogr Virol Basel, Karger 2001; 22: 160-182.
64. Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 1994; 86: 1228-1233. (Pubitemid 24253698)
65. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994; 54: 6017-6021. (Pubitemid 24378619)
66. Lorence RM, Pecora AL, Major PP, Hotte SJ, Laurie SA, Roberts MS, et al. Overview of phase I studies of intravenous adminstration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003; 5: 618-624. (Pubitemid 38094433)
67. Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18: 863-868.
68. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med (Cambridge, MA) 1998; 4: 783-794. (Pubitemid 29180125)
69. Schirrmacher V, Ahlert T, Probstle T, Steiner HH, Herold-Mende C, Gerhards R et al. Immunization with virus-modified tumor cells. Semin Oncol 1998; 25: 677-696. (Pubitemid 28565548)
70. Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983; 52: 856-860. (Pubitemid 13037651)
71. Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992; 9: 169-171. (Pubitemid 23122622)
72. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology 1993; 36: 193-214. (Pubitemid 24054577)
73. Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 1992; 35: 325-330.
74. Kirchner HH, Anton P, Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 1995; 13: 171-173.
75. Haas C, Strauss G, Moldenhauer G, Iorio RM, Schirrma-cher V. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. Clin Cancer Res 1998; 4: 721-730. (Pubitemid 28193573)
76. Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 1993; 17: 619-627. (Pubitemid 2011585)
77. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966. (Pubitemid 24258091)
78. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-448. (Pubitemid 28211196)
79. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1994; 1: 323-331.
80. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978. (Pubitemid 35462560)
81. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266. (Pubitemid 120031840)
82. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from trigger-ing total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89: 3266-3270.
83. McKie EA, MacLean AR, Lewis AD, Cruickshank G, Rampling R, Barnett SC et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours-evaluation of a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-752. (Pubitemid 26300766)
84. Martuza RL. Act locally, think globally. Nat Med 1997; 3: 1323. (Pubitemid 28011029)
85. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP et al. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adeno-viruses. Exp Cell Res 1999; 252: 1-12. (Pubitemid 29485121)
86. Pennisi E. Will a twist of viral fate lead to a new cancer treatment? Science 1996; 274: 342-343. (Pubitemid 26353329)
87. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
88. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 1996; 93: 11313-11318. (Pubitemid 26347118)
89. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-1415.
90. Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest J Tech Methods Pathol 1995; 73: 636-648.
91. Lambright ES, Kang EH, Force S, Lanuti M, Caparrelli D, Kaiser LR et al. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol Ther 2000; 2: 387-393.
92. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 1997; 108: 933-937. (Pubitemid 27272413)
93. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Human Gene Ther 1998; 9: 2177-2185. (Pubitemid 28498004)
94. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Human Gene Ther 1999; 10: 385-393. (Pubitemid 29097317)
95. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 1998; 228: 366-374. (Pubitemid 30191699)
96. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523-1537. (Pubitemid 29282962)
97. Lambright ES, Caparrelli DJ, Abbas AE, Toyoizumi T, Coukos G, Molnar-Kimber KL et al. Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system. Ann Thorac Surg 1999; 68: 1756-1760; discussion 1761-1752.
98. Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 2002; 53: 95-100.
99. Coukos G, Rubin SC, Molnar-Kimber KL. Application for recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system. Gene Ther Mol Biol 1999; 3: 79-89.
100. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH et al. Use of a 'replication-restricted' herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57: 466-471. (Pubitemid 27081665)
101. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemother-apeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Human Gene Ther 1999; 10: 3013-3029.
102. Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999; 59: 2055-2058. (Pubitemid 29217663)
103. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224: 323-329; discussion 329-330.
104. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9: 398-406. (Pubitemid 34414038)
105. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Human Gene Ther 1999; 10: 2741-2755.
106. Endo T, Toda M, Watanabe M, Iizuka Y, Kubota T, Kitajima M et al. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 2002; 9: 142-148. (Pubitemid 34141916)
107. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457-4464. (Pubitemid 28217304)
108. Carew JF, Kooby DA, Halterman MW, Kim SH, Federoff HJ, Fong Y. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001; 4: 250-256. (Pubitemid 32851289)
109. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res 2001; 61: 153-161. (Pubitemid 32095713)
110. Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Human Gene Ther 2001; 12: 253-265. (Pubitemid 32163897)
111. Bennett JJ, Malhotra S, Wong RJ, Delman K, Zager J, St-Louis M et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001; 233: 819-826. (Pubitemid 32494563)
112. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97: 2208-2213. (Pubitemid 30134047)
113. Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001; 3: 451-456. (Pubitemid 32988816)
114. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162-169.
115. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 1998; 5: 160-165. (Pubitemid 28077742)
116. Bradley JD, Kataoka Y, Advani S, Chung SM, Arani RB, Gillespie GY et al. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 1999; 5: 1517-1522. (Pubitemid 29282961)
117. Chung SM, Advani SJ, Bradley JD, Kataoka Y, Vashistha K, Yan SY et al. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther 2002; 9: 75-80. (Pubitemid 34145170)
118. Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Human Gene Ther 2002; 13: 627-639. (Pubitemid 34264313)
119. Spear MA, Sun F, Eling DJ, Gilpin E, Kipps TJ, Chiocca EA et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther 2000; 7: 1051-1059. (Pubitemid 30483485)
120. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000; 6: 3342-3353. (Pubitemid 30637766)
121. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpes-virus. Cancer Res 2000; 60: 2790-2795. (Pubitemid 30395793)
122. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447-5452. (Pubitemid 32694925)
123. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4: 222-228. (Pubitemid 127667118)
124. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861-3865. (Pubitemid 29393540)
125. Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther 2000; 7: 939-946. (Pubitemid 30437296)
126. Fruh K, Ahn K, Djaballah H, Sempe P, van Endert PM, Tampe R et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415-418.
127. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994; 77: 525-535.
128. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396-6401. (Pubitemid 32488248)
129. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000; 105: 841-846. (Pubitemid 30203053)
130. Berger C, Xuereb S, Johnson DC, Watanabe KS, Kiem HP, Greenberg PD et al. Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes. J Virol 2000; 74: 4465-4473. (Pubitemid 30237871)
131. Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005; 115: 1903-1912. (Pubitemid 40979730)
132. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747. (Pubitemid 44876843)
133. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encod-ing, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
134. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307-315. (Pubitemid 8167247)
135. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29-37.
136. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe Jr JE, Dermody TS. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005; 191: 1221-1224.
137. Jackson GG, Muldoon RL. Viruses causing common respiratory infection in man. IV. Reoviruses and Adeno-viruses. J Infect Dis 1973; 128: 811-866.
138. Adams DJ, Spendlove JC, Spendlove RS, Barnett BB. Aerosol stability of infectious and potentially infectious reovirus particles. Appl Environ Microbiol 1982; 44: 903-908. (Pubitemid 13213360)
139. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351-3362. (Pubitemid 28279509)
140. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334. (Pubitemid 28524498)
141. Hirasawa K, Yoon C, Nishikawa SG, Waisman DM, Lee PW. Reovirus therapy of metastatic cancer models in immune-competent mice. Proc Am Assoc Cancer Res 2001; 42: 2427.
142. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696-1701. (Pubitemid 34408491)
143. Morris DG, Forsyth PA, Paterson AHG, Fonseca K, DiFrancesco LM, Thompson BG et al. A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histolo-gically confirmed malignancies. Proc Am Soc Clin Oncol 2002; 21: 24. Abstract 92.
144. Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008; 16: 627-632. (Pubitemid 351315004)
145. Soefje SA, Sarantopoulos J, Sankhala KK, Mita AC, Mahany JJ, Carmona T et al. A phase II study of intravenous reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol 2008; 26: Abstract 10568.
146. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127-7137.
147. Arkenau H, Evans J, Lokelma M, Roxburgh P, Morisson R, Coffey M et al. A phase I study of the combination of intravenous Reolysin (REO) and gemcita-bine (GEM) in patients (pts) with advanced cancer. J Clin Oncol, 2009 ASCO Ann Meeting Proc 2009; 27 (15S, May 20 Suppl): Abstract 3584.
148. Comins C, Spicer J, Protheroe A, Mukherji D, Coffey M, Thompson B et al. A phase I study to evaluate systemic wild-type reovirus (REOLYSIN) in combination with docetaxel in patients with advanced malignancies. J Immunother 2008; 31: 951.
149. Karapanagiotou E, Pandha H, Hall G, Chester J, Melcher A, de Bono J et al. Phase I trial of oncolytic reovirus (reolysin) in combination with carboplatin/paclitaxel in patients with advanced solid cancers. J Immunother 2008; 31: 952.
150. Saunders M, Anthoney A, Coffey M, Mettinger K, Thompson B, Melcher A et al. Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J Clin Oncol 2009 ASCO Ann Meeting Proc 2009; 27(15S, May 20 Suppl) e14514.
151. Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 2007; 99: 1623-1633.
152. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55: 295-303.
153. Rudin CM, Senzer N, Stephenson J, Loesch D, Burroughs K, Police SR et al. Phase I study of intravenous Seneca Valley virus (NTX-010), a replication competent oncolytic virus, in patients with neuroendocrine (NE) cancers. J Clin Oncol 2009; 27(15s, Suppl): Abstract 4629.
154. Schutz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC et al. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer Gene Ther 2001; 8: 655-661. (Pubitemid 32912239)
155. Timiryasova TM, Chen B, Fodor I. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells. J Gene Med 2001; 3: 468-477. (Pubitemid 33684783)
156. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HJ, Mulholland SG, Lattime EC Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol2001; 166: 1291-1295. (Pubitemid 32862158)
157. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D et al. Surgical adjuvant active specific immunotherapy for patients with stage III mela-noma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187: 69-77; discussion 77-69.
158. Mastrangelo MJ, Maguire Jr HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-422. (Pubitemid 129667814)
159. Wallack MK, Bash JA, Leftheriotis E, Seigler H, Bland K, Wanebo H et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987; 122: 1460-1463. (Pubitemid 18058300)
160. Wallack MK, Scoggin SD, Sivanandham M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mt Sinai J Med NY 1992; 59: 227-233. (Pubitemid 23036005)
161. Scoggin SD, Sivanandham M, Sperry RG, Wallack MK. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate. Ann Plast Surg 1992; 28: 108-109.
162. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7: 663-670. (Pubitemid 30314050)
163. van Ophoven A, Gitlitz B, Tso CL, Dolan N, Stiles A, Kulmaticki A et al. Phase I dose escalation trials of vaccinia (VV)-MUC-1-IL-2 gene therapy in patient with advanced MUC-1+ prostate cancer (CAP) and non small cell lung cancer (NSCLC) B. Proc Am Soc Clin Oncol 2000; 19: abstract 1811.
164. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6: 1632-1638. (Pubitemid 30305054)
165. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53: 109-117.
166. Naik AM, Xu H, Alexander HR, Bartlett DL. A mutant vaccinia virus with improved tumor selectivity. Proc 54th Ann SSO Cancer Symp 2001; Washington, DC
167. Freund YR, Mirsalis JC, Fairchild DG, Brune J, Hokama LA, Schindler-Horvat J et al. Vaccination with a recombi-nant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. Int J Cancer 2000; 85: 508-517. (Pubitemid 30075129)
168. Shankar P, Schlom J, Hodge JW. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine 2001; 20: 744-755. (Pubitemid 34015814)
169. Kalus RM, Kantor JA, Gritz L, Gomez Yafal A, Mazzara GP, Schlom J et al. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 1999; 17: 893-903. (Pubitemid 29074744)
170. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-629. (Pubitemid 26412334)
171. Fisher KD. Polymer-coated adenovirus can be programmed to infect cells using selected ligands and shows extended plasma circulation following intravenous injection. Third International Meeting on Oncolytic Viruses as Cancer Therapeutics, Banff, Alberta 2003, p 17.
172. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004; 11: 1256-1263. (Pubitemid 39173432)
173. Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. JDrug Target 2007; 15: 546-551. (Pubitemid 47209055)
174. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 2007; 67: 8783-8790. (Pubitemid 47437454)
175. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic Cancer Biol Ther 2003; 2 (4 Suppl 1): S23-S37.
176. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578. (Pubitemid 26365552)
177. Haisma HJ, Pinedo HM, Rijswijk A, der Meulen-Muileman I, Sosnowski BA, Ying W et al. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 1999; 6: 1469-1474. (Pubitemid 29396735)
178. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997; 57: 1447-1451. (Pubitemid 27175559)
179. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-5748. (Pubitemid 29006415)
180. Grill J, Van Beusechem VW, Van Der Valk P, Dirven CM, Leonhart A, Pherai DS et al. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res 2001; 7: 641-650. (Pubitemid 32707990)
181. Sebestyen Z, de Vrij J, Magnusson M, Debets R, Willemsen R. An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res 2007; 67: 11309-11316. (Pubitemid 350248557)
182. Rogers RP, Strominger JL, Speck SH. Epstein-Barr virus in B lymphocytes: viral gene expression and function in latency. Adv Cancer Res 1992; 58: 1-26.
183. Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Human Gene Ther 2007; 18: 589-602. (Pubitemid 47187091)
184. Ulasov IV, Rivera AA, Han Y, Curiel DT, Zhu ZB, Lesniak MS. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg 2007; 107: 617-627. (Pubitemid 47451047)
185. Fujiwara T, Tanaka N. Theranostic application of telomerase-specific oncolytic adenovirus for human cancer. Nippon Rinsho 2007; 65: 1913-1922.
186. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WS. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378-387. (Pubitemid 36259672)
187. Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007; 15: 1982-1990. (Pubitemid 350011738)
188. Delgado-Enciso I, Cervantes-Garcia D, Martinez-Davila IA, Ortiz-Lopez R, Alemany-Bonastre R, Silva-Platas CI et al. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms. J Gene Med 2007; 9: 852-861. (Pubitemid 47543252)
189. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Human Gene Ther 2003; 14: 1415-1428. (Pubitemid 37268220)
190. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53: 962-967. (Pubitemid 23087892)
191. Gao Z, Fields JZ, Boman BM. Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarci-noma cells. Int J Cancer 1999; 82: 346-352. (Pubitemid 29302975)
192. Savontaus MJ, Sauter BV, Huang TG, Woo SL. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther 2002; 9: 972-979. (Pubitemid 34812288)
193. Thompson GA, Boston RS, Lyznik LA, Hodges TK, Larkins BA. Analysis of promoter activity from an alpha-zein gene 5' flanking sequence in transient expression assays. Plant Mol Biol 1990; 15: 755-764.
194. Thompson EM, Nagata S, Tsuji FI. Vargula hilgendorfii luciferase: a secreted reporter enzyme for monitoring gene expression in mammalian cells. Gene 1990; 96: 257-262.
195. Shirakawa T, Hamada K, Zhang Z, Okada H, Tagawa M, Kamidono S et al. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin Cancer Res 2004; 10: 4342-4348. (Pubitemid 38878872)
196. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001; 61: 6194-6200. (Pubitemid 32762557)
197. Kawakami K, Takeshita F, Puri RK. Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain. J Biol Chem 2001; 276: 25114-25120.
198. Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res 2006; 66: 9736-9743. (Pubitemid 44623675)
199. Tong AW. Small RNAs and non-small cell lung cancer. Curr Mol Med 2006; 6: 339-349.
200. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472. (Pubitemid 32995035)
201. Ther M (ed). A Phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy. Sixth Annual Meeting of the American Society of Gene Therapy; June 4-8; Washington, DC, 2003.
202. Ther M (ed). Circulating oncolytic and wild type adenovirus levels in clinical trial patients treated with CG7870. Sixth Annual Meeting of the American Society of Gene Therapy; June 4-8; Washington, DC, 2003.
203. Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolo-mide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 2007; 67: 11499-11504.
204. Pan Q, Liu B, Liu J, Cai R, Liu X, Qian C Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol 2008; 47: 135-144.
205. Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 2007; 304: 315-323. (Pubitemid 47456880)
206. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-9556. (Pubitemid 23315823)
207. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994; 54: 440-452. (Pubitemid 24131349)
208. Lamfers ML, Idema S, Bosscher L, Heukelom S, Moenir-alm S, van der Meulen-Muileman IH et al. Differential effects of combined Ad5-delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res 2007; 13: 7451-7458.